Skip to main content

CAR T-cell therapy

Edited by:  
Peilong Lai, MD, PhD, Guangdong Provincial People's Hospital, China

Submission Status: Closed   |   Submission Deadline: Closed


Experimental Hematology & Oncology is calling for submissions to our collection on "CAR T-cell therapy." CAR T-cell research is moving rapidly from bench to bedside. This Experimental Hematology & Oncology collection welcomes studies covering the latest development in CAR T-cell therapy. 

Articles published in the collection have already gone through the systematic peer review process of the journal.

About the collection

Experimental Hematology & Oncology is calling for submissions to our Collection on "CAR T-cell therapy." 

CAR T-cell research is moving rapidly from bench to bedside. This Experimental Hematology & Oncology collection welcomes studies covering the latest development in CAR T-cell therapy.


Image credit: © Meletios Verras / Getty Images / iStock

  2. Brexucabtagene autoleucel CAR-T therapy is highly efficacious in overcoming resistance to Bruton’s tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma. However, many patients relapse post CAR-T therapy w...

    Authors: Fangfang Yan, Vivian Jiang, Alexa Jordan, Yuxuan Che, Yang Liu, Qingsong Cai, Yu Xue, Yijing Li, Joseph McIntosh, Zhihong Chen, Jovanny Vargas, Lei Nie, Yixin Yao, Heng-Huan Lee, Wei Wang, JohnNelson R. Bigcal…
    Citation: Experimental Hematology & Oncology 2024 13:14
    Content type: Research Published on:

  4. CD19-targeted chimeric receptor antigen (CAR)-T cell therapy has shown remarkable clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies. However, 30%–60% of patients eventually...

    Authors: Jia Xu, Wenjing Luo, Chenggong Li and Heng Mei
    Citation: Experimental Hematology & Oncology 2023 12:90
    Content type: Review Published on:

  5. CAR T cell therapy has been successfully used in the treatment of hematological malignancies, and the strategy that deletion of inhibitory receptor on the CAR T cell surface, such as PD-1, greatly enhance the ...

    Authors: Ming Liu, Linlin Zhang, Mingtian Zhong, Yihao Long, Wenhui Yang, Ting Liu, Xingxu Huang and Xiaodong Ma
    Citation: Experimental Hematology & Oncology 2023 12:88
    Content type: Correspondence Published on:

  6. Immunosuppression induced by programmed cell death protein 1 (PD1) presents a significant constraint on the effectiveness of chimeric antigen receptor (CAR)-T therapy. The potential of combining PD1/PDL1 (Prog...

    Authors: Ang Zhang, Shenyu Wang, Yao Sun, Yikun Zhang, Long Zhao, Yang Yang, Yijian Zhang, Lei Xu, Yangyang Lei, Jie Du, Hu Chen, Lian Duan, Mingyi He, Lintao Shi, Lei Liu, Quanjun Wang…
    Citation: Experimental Hematology & Oncology 2023 12:85
    Content type: Research Published on:

  7. Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin lymphoma subtype which remains incurable despite multimodal approach including chemoimmunotherapy followed by stem cell transplant, targeted approaches s...

    Authors: Wing Keung Chan, Jessica Williams, Kinnari Sorathia, Betsy Pray, Kaled Abusaleh, Zehua Bian, Archisha Sharma, Ian Hout, Shamama Nishat, Walter Hanel, Shelby L. Sloan, Aneeq Yasin, Nathan Denlinger, Xiaoli Zhang, Natarajan Muthusamy, Sumithira Vasu…
    Citation: Experimental Hematology & Oncology 2023 12:79
    Content type: Research Published on:

  8. Chimeric antigen receptor (CAR)-T cell therapy is one of the most promising advances in cancer treatment. It is based on genetically modified T cells to express a CAR, which enables the recognition of the spec...

    Authors: Cristina Aparicio, Carlos Acebal and Margarita González-Vallinas
    Citation: Experimental Hematology & Oncology 2023 12:73
    Content type: Review Published on:

Submission Guidelines

Back to top

Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "CAR-T cell therapy" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published. 

The Guest Editor has no competing interests with the submissions which he handles through the peer review process. The peer review of any submissions for which the Guest Editor has competing interests is handled by another Editorial Board Member who has no competing interests.